{
  "1X8.F": {
    "city": "Nedlands",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Creso Pharma Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CRESO PHARMA LTD",
    "state": "WA",
    "summary": "Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, North America, and the Asia Pacific. The company develops and commercializes therapeutic products; and cultivates and harvests cannabis plants, as well as supplies dried cannabis plant retail products. Its products include anibidiol, a complementary feed product for companion animals; cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and zinc that reduces stress and supports psychological and nervous functions in humans; and topical and skin care products, which include cannaDOL, a CBD-based topical gel associated with a mixture of cooling and warming essential oils. The company also offers nutraceutical products, such as cannaQIX, a hemp oil-derived food supplement under the Cannamics brand. Creso Pharma Limited was incorporated in 2015 and is headquartered in Nedlands, Australia.",
    "website": "http://www.cresopharma.com",
    "zipcode": "6009"
  },
  "AC8.AX": {
    "city": "West Perth",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "AusCann Group Holdings Ltd",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AUSCANN FPO",
    "state": "WA",
    "summary": "AusCann Group Holdings Ltd, a pharmaceutical company, researches, develops, cultivates, produces, and distributes cannabinoid-based pharmaceuticals in Australia and internationally. It offers hard-shell capsules using Neuvis technology for the treatment of chronic neuropathic pain. The company is based in West Perth, Australia.",
    "website": "http://auscann.com.au",
    "zipcode": "6005"
  },
  "ACNNF": {
    "city": "West Perth",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "AusCann Group Holdings Ltd",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AUSCANN GROUP HOLDINGS LTD",
    "state": "WA",
    "summary": "AusCann Group Holdings Ltd, a pharmaceutical company, researches, develops, cultivates, produces, and distributes cannabinoid-based pharmaceuticals in Australia and internationally. It offers hard-shell capsules using Neuvis technology for the treatment of chronic neuropathic pain. The company is based in West Perth, Australia.",
    "website": "http://auscann.com.au",
    "zipcode": "6005"
  },
  "AGH.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Althea Group Holdings Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ALTHEA FPO",
    "state": "VIC",
    "summary": "Althea Group Holdings Limited cultivates, produces, supplies, imports, and exports pharmaceutical grade medicinal cannabis in Australia, the United Kingdom, and Canada. It also offers a range of education, access, and management services to support eligible patients, healthcare professionals, and pharmacies in navigating medicinal cannabis treatment pathways through Concierge, an online service, as well as Medic, an online education. Althea Group Holdings Limited was founded in 2017 and is based in Melbourne, Australia.",
    "website": "http://www.althea.life",
    "zipcode": "3000"
  },
  "ANP.AX": {
    "city": "Toorak",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Antisense Therapeutics Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ANTISENSE FPO",
    "state": "VIC",
    "summary": "Antisense Therapeutics Limited, a biopharmaceutical company, engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d that has completed Phase IIa for the treatment of multiple sclerosis, Duchennes Muscular Dystrophy, multiple sclerosis, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited is based in Toorak, Australia.",
    "website": "http://www.antisense.com.au",
    "zipcode": "3142"
  },
  "APH.AX": {
    "city": "Geelong",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Australian Primary Hemp Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "APHEMP FPO",
    "state": "VIC",
    "summary": "Australian Primary Hemp Limited manufactures and distributes hemp products under the Australian Primary Hemp brand to retail, wholesale, and white label customers in Australia. The company offers hemp seeds, cold pressed hemp oil, hemp fiber powder, hemp flour, hemp protein powder, hemp and bush balm mint hand sanitizers, hemp boost, hemp balance, and hemp and honey nut bars. It is also involved in the cultivation and production of hemp; handling various areas of hemp seed selection, farming, processing, and distribution; hemp contract packaging; and bulk and retail sale of edible hemp products. The company was founded in 2016 and is headquartered in Geelong, Australia.",
    "website": "http://www.ausprimaryhemp.com.au",
    "zipcode": "3220"
  },
  "ATHJF": {
    "city": "Toorak",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Antisense Therapeutics Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ANTISENSE THERAPEUTICS",
    "state": "VIC",
    "summary": "Antisense Therapeutics Limited, a biopharmaceutical company, engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d that has completed Phase IIa for the treatment of multiple sclerosis, Duchennes Muscular Dystrophy, multiple sclerosis, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited is based in Toorak, Australia.",
    "website": "http://www.antisense.com.au",
    "zipcode": "3142"
  },
  "AWY.F": {
    "city": "Toorak",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Antisense Therapeutics Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ANTISENSE THERAPEUTICS",
    "state": "VIC",
    "summary": "Antisense Therapeutics Limited, a biopharmaceutical company, engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d that has completed Phase IIa for the treatment of multiple sclerosis, Duchennes Muscular Dystrophy, multiple sclerosis, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited is based in Toorak, Australia.",
    "website": "http://www.antisense.com.au",
    "zipcode": "3142"
  },
  "CAN.AX": {
    "city": "Bundoora",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Cann Group Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CANN GROUP FPO",
    "state": "VIC",
    "summary": "Cann Group Limited engages in research and development, cultivation and production, manufacturing, clinical evaluation, processing, packaging, and distribution and supply of medicinal cannabis for various diseases and medical conditions in Australia. The company was founded in 2014 and is based in Bundoora, Australia.",
    "website": "http://www.canngrouplimited.com",
    "zipcode": "3083"
  },
  "CAU.AX": {
    "city": "South Yarra",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Cronos Australia Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "CRONOS FPO",
    "state": "VIC",
    "summary": "Cronos Australia Limited operates as a medicinal cannabis company in Australia and Asia. The company operates through Medicinal Cannabis and Clinics segments. It distributes  PEACE NATURALS brand medicinal cannabis products; develops and sells medicinal cannabis products; and operates medicinal cannabis clinics. The company was incorporated in 2018 and is headquartered in South Yarra, Australia.",
    "website": "http://www.cronosaustralia.com",
    "zipcode": "3141"
  },
  "CGB.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Cann Global Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "CANNGLOBAL FPO",
    "state": "NSW",
    "summary": "Cann Global Limited operates in medicinal cannabis and hemp food industries in Australia and internationally. The company operates through Hemp and Medical Cannabis Products, and Mining Exploration and Evaluation segments. It grows and cultivates hemp and medical cannabis products; and provides plant-based food and skin care products. The company also engages in the exploration and development of bauxite. In addition, it holds interests in the South Johnstone Project located in Queensland; and the New England Bauxite Project located in the New South Wales. The company was formerly known as Queensland Bauxite Limited and changed its name to Cann Global Limited in January 2019. Cann Global Limited was incorporated in 2007 and is based in Sydney, Australia.",
    "website": "http://www.canngloballimited.com",
    "zipcode": "2000"
  },
  "CNGGF": {
    "city": "Bundoora",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Cann Group Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CANN GROUP LTD",
    "state": "VIC",
    "summary": "Cann Group Limited engages in research and development, cultivation and production, manufacturing, clinical evaluation, processing, packaging, and distribution and supply of medicinal cannabis for various diseases and medical conditions in Australia. The company was founded in 2014 and is based in Bundoora, Australia.",
    "website": "http://www.canngrouplimited.com",
    "zipcode": "3083"
  },
  "COPHF": {
    "city": "Nedlands",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Creso Pharma Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CRESO PHARMA LTD",
    "state": "WA",
    "summary": "Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, North America, and the Asia Pacific. The company develops and commercializes therapeutic products; and cultivates and harvests cannabis plants, as well as supplies dried cannabis plant retail products. Its products include anibidiol, a complementary feed product for companion animals; cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and zinc that reduces stress and supports psychological and nervous functions in humans; and topical and skin care products, which include cannaDOL, a CBD-based topical gel associated with a mixture of cooling and warming essential oils. The company also offers nutraceutical products, such as cannaQIX, a hemp oil-derived food supplement under the Cannamics brand. Creso Pharma Limited was incorporated in 2015 and is headquartered in Nedlands, Australia.",
    "website": "http://www.cresopharma.com",
    "zipcode": "6009"
  },
  "CPH.AX": {
    "city": "Nedlands",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Creso Pharma Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CRESO FPO",
    "state": "WA",
    "summary": "Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, North America, and the Asia Pacific. The company develops and commercializes therapeutic products; and cultivates and harvests cannabis plants, as well as supplies dried cannabis plant retail products. Its products include anibidiol, a complementary feed product for companion animals; cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and zinc that reduces stress and supports psychological and nervous functions in humans; and topical and skin care products, which include cannaDOL, a CBD-based topical gel associated with a mixture of cooling and warming essential oils. The company also offers nutraceutical products, such as cannaQIX, a hemp oil-derived food supplement under the Cannamics brand. Creso Pharma Limited was incorporated in 2015 and is headquartered in Nedlands, Australia.",
    "website": "http://www.cresopharma.com",
    "zipcode": "6009"
  },
  "CVJ.F": {
    "city": "Bundoora",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Cann Group Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CANN GROUP LTD",
    "state": "VIC",
    "summary": "Cann Group Limited engages in research and development, cultivation and production, manufacturing, clinical evaluation, processing, packaging, and distribution and supply of medicinal cannabis for various diseases and medical conditions in Australia. The company was founded in 2014 and is based in Bundoora, Australia.",
    "website": "http://www.canngrouplimited.com",
    "zipcode": "3083"
  },
  "E8M.F": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Elixinol Wellness Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ELIXINOL WELLNESS LTD.",
    "state": "NSW",
    "summary": "Elixinol Global Limited, through its subsidiaries, manufactures and distributes industrial hemp-based nutraceutical, dietary supplements, and skincare products in the Americas, Europe, and Australia. It distributes hemp-derived cannabidiol products under the Elixinol brand. The company was incorporated in 2017 and is headquartered in Sydney, Australia.",
    "website": "http://www.elixinolglobal.com",
    "zipcode": "2000"
  },
  "ECS.AX": {
    "city": "Launceston",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "ECS Botanics Holdings Ltd",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ECSBOTANIC FPO",
    "state": "TAS",
    "summary": "ECS Botanics Holdings Ltd, an agribusiness and hemp food company, cultivates and processes industrial hemp in Australia. It also supplies bulk hemp foods for cafes, whole food suppliers, food brands, or food manufacturers, as well as hemp seed to licensed operators for processing and sowing. The company is based in Launceston, Australia.",
    "website": "http://ecsbotanics.com.au",
    "zipcode": "7302"
  },
  "ELLXF": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Elixinol Wellness Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ELIXINOL WELLNESS LTD",
    "state": "NSW",
    "summary": "Elixinol Global Limited, through its subsidiaries, manufactures and distributes industrial hemp-based nutraceutical, dietary supplements, and skincare products in the Americas, Europe, and Australia. It distributes hemp-derived cannabidiol products under the Elixinol brand. The company was incorporated in 2017 and is headquartered in Sydney, Australia.",
    "website": "http://www.elixinolglobal.com",
    "zipcode": "2000"
  },
  "EOF.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Ecofibre Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ECOFIBRE FPO",
    "state": "NSW",
    "summary": "Ecofibre Limited, together with its subsidiaries, engages in breeding, growing, processing, and distributing hemp products in the United States and Australia. It offers protein powders, dehulled hemp seeds, and hemp seed oil products. The company also produces hemp nutraceutical products for human and pet consumption, as well as topical creams and salves; and develops hemp related fiber products. It sells its products through wholesalers and distributors, as well as pharmacy stores under the Ananda Food and Woolworths Macro brand names. The company was founded in 2009 and is based in Sydney, Australia.",
    "website": "http://www.ecofibre.com",
    "zipcode": "2000"
  },
  "EOFBF": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Ecofibre Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ECOFIBRE LTD",
    "state": "NSW",
    "summary": "Ecofibre Limited, together with its subsidiaries, engages in breeding, growing, processing, and distributing hemp products in the United States and Australia. It offers protein powders, dehulled hemp seeds, and hemp seed oil products. The company also produces hemp nutraceutical products for human and pet consumption, as well as topical creams and salves; and develops hemp related fiber products. It sells its products through wholesalers and distributors, as well as pharmacy stores under the Ananda Food and Woolworths Macro brand names. The company was founded in 2009 and is based in Sydney, Australia.",
    "website": "http://www.ecofibre.com",
    "zipcode": "2000"
  },
  "EPN.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Epsilon Healthcare Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "EPSILON FPO",
    "state": "NSW",
    "summary": "Epsilon Healthcare Limited operates as a healthcare and pharmaceuticals company primarily in Australia and Canada. It engages in the manufacture and distribution of hydroponics equipment, materials, and nutrients; and development and delivery of medicinal cannabis, as well as provides turnkey cultivation solutions. The company was formerly known as THC Global Group Limited and changed its name to Epsilon Healthcare Limited in February 2021. Epsilon Healthcare Limited was incorporated in 2016 and is based in Sydney, Australia.",
    "website": "http://www.epsilonhealthcare.com.au",
    "zipcode": "2000"
  },
  "EXL.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Elixinol Wellness Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ELIXINOL FPO",
    "state": "NSW",
    "summary": "Elixinol Global Limited, through its subsidiaries, manufactures and distributes industrial hemp-based nutraceutical, dietary supplements, and skincare products in the Americas, Europe, and Australia. It distributes hemp-derived cannabidiol products under the Elixinol brand. The company was incorporated in 2017 and is headquartered in Sydney, Australia.",
    "website": "http://www.elixinolglobal.com",
    "zipcode": "2000"
  },
  "H5O.F": {
    "city": "West Perth",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MGC Pharmaceuticals Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MGC PHARMACEUTICALS LTD",
    "state": "WA",
    "summary": "MGC Pharmaceuticals Limited, together with its subsidiaries, produces and supplies phytocannabinoid derived medicines in Australia and Slovenia. It provides pharmaceutical products, such as Tetrinol for the treatment of cachexia; MXOT01GB01 to treat glioblastoma; MXOT02ME01 for the treatment of melanoma cancer; MXOT03PC01 to treat prostate cancer; TopiCann for the topical treatment of eczema and inflamed skin; and InCann, a biactive capsule to treat Chron's and IBS. The company's products under development include CannEpil, which is in Phase IIb clinical trial for the treatment in children and adolescents with refectory epilepsy; CogniCann that is in Phase II clinical trial to treat dementia and Alzheimer's diseases; and ArtemiC, which is in Phase II clinical trial for the treatment COVID-19. It has strategic collaborative partnership agreements Epilepsy Action Australia, Royal Melbourne Institute of Technology, the University of Notre Dame in Western Australia, as well as the National Institute of Biology & University Medical Centre, Ljubljana Slovenia. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.",
    "website": "http://www.mgcpharma.com.au",
    "zipcode": "6005"
  },
  "IDT.AX": {
    "city": "Boronia",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "IDT Australia Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "IDT AUST FPO",
    "state": "VIC",
    "summary": "IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) and finished dose form products in Australia and internationally. The company offers analytical method development, stability chambers, and chemistry and microbiology quality control laboratory services, as well as pharmaceutical development services in all dosage forms. Its services also include project management, chemical, analytical chemistry, pharmacy, clinical packaging, and regulatory affairs. In addition, the company offers medical cannabis products; and various contract manufacturing services. IDT Australia Limited was founded in 1975 and is headquartered in Boronia, Australia.",
    "website": "http://www.idtaus.com.au",
    "zipcode": "3155"
  },
  "IHL.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Incannex Healthcare Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "INHEALTH FPO",
    "state": "VIC",
    "summary": "Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's therapeutic products in clinical trials include IHL-42X for obstructive sleep apnea; IHL-216A for traumatic brain injury; IHL-675A for sepsis associated acute respiratory distress syndrome; and IHL-493C for temporomandibular joint dysfunction. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea. Incannex Healthcare Limited has a partnership with Monash Trauma Group at the Department of Neuroscience, Monash University to conduct an in vivo study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited is based in Melbourne, Australia.",
    "website": "http://www.incannex.com.au",
    "zipcode": "3000"
  },
  "IQI.F": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Incannex Healthcare Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "INCANNEX HEALTHCARE LTD.",
    "state": "VIC",
    "summary": "Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's therapeutic products in clinical trials include IHL-42X for obstructive sleep apnea; IHL-216A for traumatic brain injury; IHL-675A for sepsis associated acute respiratory distress syndrome; and IHL-493C for temporomandibular joint dysfunction. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea. Incannex Healthcare Limited has a partnership with Monash Trauma Group at the Department of Neuroscience, Monash University to conduct an in vivo study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited is based in Melbourne, Australia.",
    "website": "http://www.incannex.com.au",
    "zipcode": "3000"
  },
  "IVIXF": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Invion Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "INVION LTD",
    "state": "VIC",
    "summary": "Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a chlorophyll-based photosensitizer to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.",
    "website": "http://www.inviongroup.com",
    "zipcode": "3102"
  },
  "IVX.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Invion Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "INVION FPO",
    "state": "VIC",
    "summary": "Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a chlorophyll-based photosensitizer to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.",
    "website": "http://www.inviongroup.com",
    "zipcode": "3102"
  },
  "LGP.AX": {
    "city": "West Perth",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Little Green Pharma Ltd",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "LITTLEGRN FPO",
    "state": "WA",
    "summary": "Little Green Pharma Ltd engages in the research and development, cultivation, production, manufacturing, and distribution of medicinal cannabis products in Australia and internationally. It offers a range of medical cannabis preparations in oil formulation under the LGP Natural and LGP Advanced names. The company was founded in 2016 and is headquartered in West Perth, Australia.",
    "website": "http://www.littlegreenpharma.com",
    "zipcode": "6005"
  },
  "LV1.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Live Verdure Ltd",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LIVEVLIM FPO",
    "state": "VIC",
    "summary": "Live Verdure Ltd develops hemp plant-based solutions in Australia. The company offers hemp seed oil, seed oil capsules, infused manuka honey, honey, drinking chocolate, seed, greens, chai powder, porridge with dried fruit, falafel, health booster, falafel spicy, porridge, flour, food, muesli, protein powder, and falafel lemon and pepper. It distributes its products under the 13 Seeds brand name. The company was formerly known as 13 Seeds Pty Ltd and changed its name to Live Verdure Ltd in October 2020. Live Verdure Ltd was incorporated in 2016 and is based in Melbourne, Australia.",
    "website": "http://www.liveverdure.com.au",
    "zipcode": "3000"
  },
  "MGCLF": {
    "city": "West Perth",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MGC Pharmaceuticals Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MGC PHARMACEUTICALS LTD",
    "state": "WA",
    "summary": "MGC Pharmaceuticals Limited, together with its subsidiaries, produces and supplies phytocannabinoid derived medicines in Australia and Slovenia. It provides pharmaceutical products, such as Tetrinol for the treatment of cachexia; MXOT01GB01 to treat glioblastoma; MXOT02ME01 for the treatment of melanoma cancer; MXOT03PC01 to treat prostate cancer; TopiCann for the topical treatment of eczema and inflamed skin; and InCann, a biactive capsule to treat Chron's and IBS. The company's products under development include CannEpil, which is in Phase IIb clinical trial for the treatment in children and adolescents with refectory epilepsy; CogniCann that is in Phase II clinical trial to treat dementia and Alzheimer's diseases; and ArtemiC, which is in Phase II clinical trial for the treatment COVID-19. It has strategic collaborative partnership agreements Epilepsy Action Australia, Royal Melbourne Institute of Technology, the University of Notre Dame in Western Australia, as well as the National Institute of Biology & University Medical Centre, Ljubljana Slovenia. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.",
    "website": "http://www.mgcpharma.com.au",
    "zipcode": "6005"
  },
  "MMJ.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MMJ Group Holdings Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "MMJGROUP FPO",
    "state": "NSW",
    "summary": "MMJ Group Holdings Limited operates as a cannabis investment company worldwide. It owns a portfolio of cannabis sector investments. The company was formerly known as MMJ PhytoTech Limited. MMJ Group Holdings Limited was incorporated in 2014 and is based in Sydney, Australia.",
    "website": "http://www.mmjgh.com.au",
    "zipcode": "2000"
  },
  "MMJJF": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MMJ Group Holdings Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "MMJ GROUP HOLDINGS LTD",
    "state": "NSW",
    "summary": "MMJ Group Holdings Limited operates as a cannabis investment company worldwide. It owns a portfolio of cannabis sector investments. The company was formerly known as MMJ PhytoTech Limited. MMJ Group Holdings Limited was incorporated in 2014 and is based in Sydney, Australia.",
    "website": "http://www.mmjgh.com.au",
    "zipcode": "2000"
  },
  "MVP.AX": {
    "city": "Scoresby",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Medical Developments International Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MEDICALDEV FPO",
    "state": "VIC",
    "summary": "Medical Developments International Limited manufactures and distributes pharmaceutical and veterinary products, and medical devices. The company operates through three segments: Pharmaceuticals, Medical Devices, and Veterinary Products. It offers asthma and COPD pressurized metered dose inhalers, as well as masks and peak flow meters for asthma management for use in home or in hospitals; Penthrox, a prescription only medicine for pain relief; medical devices; and various veterinary anesthetic machines to veterinarians. The company operates in Australia, New Zealand, the United Kingdom, rest of Europe, Canada, the Middle East, Asia, South Africa, North America, and internationally. Medical Developments International Limited was incorporated in 2003 and is headquartered in Scoresby, Australia.",
    "website": "http://medicaldev.com",
    "zipcode": "3179"
  },
  "MXC.AX": {
    "city": "West Perth",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MGC Pharmaceuticals Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MGC PHARMA FPO",
    "state": "WA",
    "summary": "MGC Pharmaceuticals Limited, together with its subsidiaries, produces and supplies phytocannabinoid derived medicines in Australia and Slovenia. It provides pharmaceutical products, such as Tetrinol for the treatment of cachexia; MXOT01GB01 to treat glioblastoma; MXOT02ME01 for the treatment of melanoma cancer; MXOT03PC01 to treat prostate cancer; TopiCann for the topical treatment of eczema and inflamed skin; and InCann, a biactive capsule to treat Chron's and IBS. The company's products under development include CannEpil, which is in Phase IIb clinical trial for the treatment in children and adolescents with refectory epilepsy; CogniCann that is in Phase II clinical trial to treat dementia and Alzheimer's diseases; and ArtemiC, which is in Phase II clinical trial for the treatment COVID-19. It has strategic collaborative partnership agreements Epilepsy Action Australia, Royal Melbourne Institute of Technology, the University of Notre Dame in Western Australia, as well as the National Institute of Biology & University Medical Centre, Ljubljana Slovenia. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.",
    "website": "http://www.mgcpharma.com.au",
    "zipcode": "6005"
  },
  "MXC.L": {
    "city": "West Perth",
    "country": "Australia",
    "currency": "GBp",
    "exchange": "LSE",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MGC Pharmaceuticals Limited",
    "market": "gb_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "MGC PHARMACEUTICALS LIMITED ORD",
    "state": "WA",
    "summary": "MGC Pharmaceuticals Limited, together with its subsidiaries, produces and supplies phytocannabinoid derived medicines in Australia and Slovenia. It provides pharmaceutical products, such as Tetrinol for the treatment of cachexia; MXOT01GB01 to treat glioblastoma; MXOT02ME01 for the treatment of melanoma cancer; MXOT03PC01 to treat prostate cancer; TopiCann for the topical treatment of eczema and inflamed skin; and InCann, a biactive capsule to treat Chron's and IBS. The company's products under development include CannEpil, which is in Phase IIb clinical trial for the treatment in children and adolescents with refectory epilepsy; CogniCann that is in Phase II clinical trial to treat dementia and Alzheimer's diseases; and ArtemiC, which is in Phase II clinical trial for the treatment COVID-19. It has strategic collaborative partnership agreements Epilepsy Action Australia, Royal Melbourne Institute of Technology, the University of Notre Dame in Western Australia, as well as the National Institute of Biology & University Medical Centre, Ljubljana Slovenia. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.",
    "website": "http://www.mgcpharma.com.au",
    "zipcode": "6005"
  },
  "NXS.AX": {
    "city": "Chatswood",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Next Science Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NEXTSCIENC FPO",
    "state": "NSW",
    "summary": "Next Science Limited, a medical technology company, researches, develops, and commercializes technologies to eradicate issues in human health caused by biofilms. The company develops its products using its Xbio Technology platform. It offers SURGX, an antimicrobial gel designed to reduce surgical site and post-surgical infections; and BACTISURE, a surgical lavage that is used to wash out the surgery site and Intramedullary canal. The company also provides BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment; and XPERIENCE, an no rinse antimicrobial solution that helps prevent surgical site and post-operative infections. It has strategic partnerships with Montana State University Center for Biofilm Engineering, Mayo Clinic, Texas Tech University Clinical Research Institute, Southwest Regional Wound Care Center, University of Florida Department of Otolaryngology, and Jacksonville Center for Clinical Research. Next Science Limited has operations in the United States and Australia. The company was founded in 2012 and is headquartered in Chatswood, Australia.",
    "website": "http://www.nextscience.com",
    "zipcode": "2067"
  },
  "NXSCF": {
    "city": "Chatswood",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Next Science Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NEXT SCIENCE LTD",
    "state": "NSW",
    "summary": "Next Science Limited, a medical technology company, researches, develops, and commercializes technologies to eradicate issues in human health caused by biofilms. The company develops its products using its Xbio Technology platform. It offers SURGX, an antimicrobial gel designed to reduce surgical site and post-surgical infections; and BACTISURE, a surgical lavage that is used to wash out the surgery site and Intramedullary canal. The company also provides BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment; and XPERIENCE, an no rinse antimicrobial solution that helps prevent surgical site and post-operative infections. It has strategic partnerships with Montana State University Center for Biofilm Engineering, Mayo Clinic, Texas Tech University Clinical Research Institute, Southwest Regional Wound Care Center, University of Florida Department of Otolaryngology, and Jacksonville Center for Clinical Research. Next Science Limited has operations in the United States and Australia. The company was founded in 2012 and is headquartered in Chatswood, Australia.",
    "website": "http://www.nextscience.com",
    "zipcode": "2067"
  },
  "PARNF": {
    "city": "Alexandria",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Parnell Pharmaceuticals Holdings Ltd",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PARNELL PHARMACEUTICALS HLDGS L",
    "state": "NSW",
    "summary": "Parnell Pharmaceuticals Holdings Ltd, a veterinary pharmaceutical company, focuses on developing, manufacturing, and commercializing various animal health solutions. The company operates through four segments: Companion Animal, Production Animal - U.S., Production Animal - Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproductive hormone products for improving cattle breeding performance; Zydax for the treatment of osteoarthritis (OA) in dogs and horses; and Glyde, a nutraceutical product aids in the treatment of OA, as well as Parnell PROcept, which adds an additional injection of estroPLAN after the first injection. The company also operates mySYNCH, a digital tool to help veterinarians and producers optimize reproduction and maximize economic gains. Parnell Pharmaceuticals Holdings Ltd was incorporated in 2009 and is headquartered in Alexandria, Australia.",
    "website": "http://www.parnell.com",
    "zipcode": "2015"
  },
  "PBP.AX": {
    "city": "Laverton North",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Probiotec Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PROBIOTEC FPO",
    "state": "VIC",
    "summary": "Probiotec Limited engages in the development, manufacture and sale of pharmaceuticals, consumer health, and nutraceutical products in Australia and internationally. The company provides contract manufacturing services for solid dose tablets, capsules, and caplets; tablets coating; blister packing; liquids, creams, gels, and ointments and suspensions; powders and powder blending; and sprays, as well as manufacturing and packaging of finished doses. It also offers analytical and stability testing services; new product formulation and production trials, and ongoing research and development services; and packaging options for human and animal nutrition products, as well as manufactures and exports a range of nutraceuticals and functional ingredient raw materials. In addition, the company provides packing services and formats, including foil, carded and clamshell blister packing, bottle filling, labelling, secondary packaging, and other services for the pharmaceutical, cosmetic, and food industries. Probiotec Limited was incorporated in 1996 and is headquartered in Laverton North, Australia.",
    "website": "http://www.probiotec.com.au",
    "zipcode": "3026"
  },
  "QA9.F": {
    "city": "Geelong",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Australian Primary Hemp Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AUSTRAL.PRIMARY HEMP LTD",
    "state": "VIC",
    "summary": "Australian Primary Hemp Limited manufactures and distributes hemp products under the Australian Primary Hemp brand to retail, wholesale, and white label customers in Australia. The company offers hemp seeds, cold pressed hemp oil, hemp fiber powder, hemp flour, hemp protein powder, hemp and bush balm mint hand sanitizers, hemp boost, hemp balance, and hemp and honey nut bars. It is also involved in the cultivation and production of hemp; handling various areas of hemp seed selection, farming, processing, and distribution; hemp contract packaging; and bulk and retail sale of edible hemp products. The company was founded in 2016 and is headquartered in Geelong, Australia.",
    "website": "http://www.ausprimaryhemp.com.au",
    "zipcode": "3220"
  },
  "SCU.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Stemcell United Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "STEMCELL FPO",
    "state": "NSW",
    "summary": "Stemcell United Limited, together with its subsidiaries, engages in the sourcing, producing, marketing, and selling of traditional medicine in Australia, Singapore, Greater China, and Malaysia. The company's products include Cannabis Sativa, an industrial hemp; Dendrobium Officinale Kimura et Migo, an orchid extract; Resina, a Daemonorops Draco Blume extract; and Caulerpa Lentillifera, a sea grape extract. The company has a collaboration agreement with Temasek Polytechnic of Singapore to conduct joint research on the application of plant stem cell technology to the cultivation and commercial farming of seagrapes in Singapore. The company was formerly known as On Q Group Limited and changed its name to Stemcell United Limited in September 2015. Stemcell United Limited was incorporated in 1984 and is headquartered in Sydney, Australia.",
    "website": "http://www.scu.com.sg",
    "zipcode": "2000"
  },
  "USZ.F": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Stemcell United Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "STEMCELL UNITED LTD",
    "state": "NSW",
    "summary": "Stemcell United Limited, together with its subsidiaries, engages in the sourcing, producing, marketing, and selling of traditional medicine in Australia, Singapore, Greater China, and Malaysia. The company's products include Cannabis Sativa, an industrial hemp; Dendrobium Officinale Kimura et Migo, an orchid extract; Resina, a Daemonorops Draco Blume extract; and Caulerpa Lentillifera, a sea grape extract. The company has a collaboration agreement with Temasek Polytechnic of Singapore to conduct joint research on the application of plant stem cell technology to the cultivation and commercial farming of seagrapes in Singapore. The company was formerly known as On Q Group Limited and changed its name to Stemcell United Limited in September 2015. Stemcell United Limited was incorporated in 1984 and is headquartered in Sydney, Australia.",
    "website": "http://www.scu.com.sg",
    "zipcode": "2000"
  },
  "UVP.F": {
    "city": "West Perth",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "AusCann Group Holdings Ltd",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AUSCANN GROUP HLDGS O.N.",
    "state": "WA",
    "summary": "AusCann Group Holdings Ltd, a pharmaceutical company, researches, develops, cultivates, produces, and distributes cannabinoid-based pharmaceuticals in Australia and internationally. It offers hard-shell capsules using Neuvis technology for the treatment of chronic neuropathic pain. The company is based in West Perth, Australia.",
    "website": "http://auscann.com.au",
    "zipcode": "6005"
  },
  "VLS.AX": {
    "city": "Kirrawee",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Vita Life Sciences Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "VLSCIENCE FPO",
    "state": "NSW",
    "summary": "Vita Life Sciences Limited, a pharmaceutical and healthcare company, engages in formulation, packaging, distribution, and sale of vitamins and supplements. It offers a range of supplements, vitamins, minerals, herbs, and superfoods. The company markets its products through pharmacies and health food stores under the Herbs of Gold, VitaHealth, VitaScience, and VitaLife brands. It operates in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, China, and internationally. Vita Life Sciences Limited was founded in 1947 and is headquartered in Kirrawee, Australia.",
    "website": "http://www.vitalifesciences.com",
    "zipcode": "2232"
  }
}
